Antidiabetes drug shows potential to treat focal segmental glomerulosclerosisRosiglitazone, the antidiabetes drug, could have the potential to guard kidney function in patients afflicted with a condition known as focal segmental glomerulosclerosis (FSGS).

This finding was disclosed in a study appearing in the January 2009 issue of the Clinical Journal of the American Society Nephrology (CJASN).

The authors said that the study results indicate that rosiglitazone warrants further investigation for the treatment of FSGS and the dose of 3 mg/m2 per day or a higher dose should be examined in later-stage studies.